How Often Can You Get Zilretta Injections: FDA Rules

Zilretta’s FDA-approved label describes it as a single intra-articular injection for osteoarthritis pain of the knee, with no specified interval for repeat dosing built into the approval itself. That means the label does not say “you can get another shot every X months.” In practice, most physicians who administer repeat injections space them roughly every three to six months, guided by clinical trial data rather than a hard regulatory schedule. The gap between the label’s silence and how the drug actually gets used in clinics is worth understanding, because it shapes both your treatment options and your conversations with your doctor.

What the FDA Label Actually Approves

Zilretta (triamcinolone acetonide extended-release) received FDA approval as a single 32 mg injection delivered into the knee joint for the management of osteoarthritis pain. The label describes a one-time, 5 mL intra-articular injection and does not include language authorizing or scheduling repeat doses at a defined frequency.¹ This is a distinction that trips people up. The FDA did not ban repeat injections; it simply approved the drug based on single-dose efficacy data. When a label says “single injection” without specifying repeat-dose intervals, it leaves the timing of subsequent doses to physician judgment.

This is not unusual for injectable drugs. Many corticosteroid formulations carry similar labeling, where the approval establishes efficacy for one dose and clinicians then decide on retreatment based on how the patient responds, how long the benefit lasts, and what the safety data support. For Zilretta specifically, the approval was anchored to a 24-week phase III trial comparing it to placebo and to standard (immediate-release) triamcinolone acetonide. That trial tested one injection and followed patients for six months, so six months became a natural boundary for the initial approval data.

The Extended-Release Mechanism and Why It Affects Timing

Zilretta is not just triamcinolone acetonide in a syringe. The drug is embedded in tiny biodegradable microspheres made of a polymer called PLGA, which dissolves slowly inside the joint over weeks.² This design keeps the steroid concentrated in the joint fluid for much longer than a standard corticosteroid shot, which tends to clear out within days.

Pharmacokinetic data from knee OA patients quantified the difference. After a single Zilretta injection, triamcinolone was still measurable in the joint fluid at 12 weeks. After a standard triamcinolone injection, only two of eight patients had any detectable drug in the joint at six weeks, and the levels were negligible.³ Peak blood levels of the steroid were also dramatically lower with Zilretta: roughly one-tenth of the peak seen with the standard formulation, reached gradually over 24 hours rather than spiking within four hours.

This prolonged local residence and reduced systemic leakage is the core rationale behind the product. It also influences repeat dosing logic. Because the drug lingers in the joint for about three months, re-injecting before that window closes means you are stacking doses in a way the trials did not study. Most clinicians wait until the previous injection’s effect has clearly worn off before considering another round, which in practice means at least 12 weeks and often longer.

What the Repeat Dosing Study Found

The strongest evidence on repeat Zilretta injections comes from a phase IIIb, open-label trial that gave patients a second injection after their first dose had worn off. Both injections were well tolerated. The study found no unexpected side effects and no significant changes on joint X-rays at one year. Pain relief after the second shot was similar in size and duration to what patients experienced after the first.⁴ Most patients reported at least a 50 percent reduction in pain after both their first and second doses.

This is reassuring but has limits. The study was open-label, meaning everyone knew they were getting the drug, which can inflate perceived benefit. It also only tested two injections total over the course of about a year. It did not test three, four, or five injections over multiple years, so long-term repeat dosing safety remains an open question. A separate review of the drug noted that findings from this study “indicated that a repeat administration of triamcinolone acetonide ER may be similarly efficacious to an initial injection without having deleterious effects on cartilage or other aspects of joint structure.”¹

The cartilage finding matters because one of the long-standing concerns about repeated corticosteroid knee injections is cartilage damage. Some studies of standard corticosteroid injections have found accelerated cartilage loss with frequent use. The fact that the Zilretta repeat-dose study showed no radiographic deterioration at 52 weeks is one of the data points clinicians weigh when deciding to re-treat.

How Zilretta Compares to Standard Steroid Injections for Pain

A common question is whether Zilretta’s extended-release design actually delivers better pain relief than a cheaper, standard corticosteroid shot. The evidence here is more complicated than the marketing suggests. In the pivotal 24-week phase III trial, Zilretta did outperform a saline placebo at 12 weeks. But compared head-to-head with standard triamcinolone acetonide, the difference was not statistically significant for the primary pain endpoint.⁵

Some secondary measures, like certain quality-of-life scores, did favor Zilretta, but the differences were small enough that reviewers questioned whether they would matter in everyday life. A review in Nature Reviews Rheumatology put it bluntly: “FX006 seems to provide better pain relief than intra-articular saline; however, the advantages over traditional formulations of triamcinolone acetonide are unclear.”⁵ The extended-release formulation costs substantially more per injection, so this comparison influences both clinical decisions and insurance coverage.

Where Zilretta appears to have a clearer advantage is not pain intensity per se but the systemic side-effect profile, particularly for patients who are sensitive to corticosteroid spikes in the bloodstream. The reduced peak blood levels and lower total systemic exposure are real, documented pharmacokinetic differences. For some patients, that pharmacokinetic advantage is the reason their doctor chooses Zilretta over a standard injection, even if the knee pain benefit is roughly comparable.

Blood Sugar Spikes and Diabetes Concerns

If you have type 2 diabetes, corticosteroid injections of any kind can send your blood sugar soaring for days. This is one area where Zilretta’s extended-release design appears to offer a meaningful practical benefit over standard formulations. A randomized study comparing the two in patients with knee OA and type 2 diabetes found that over the first three days after injection, the Zilretta group had a median glucose increase of about 92 mg/dL from baseline, while the standard triamcinolone group spiked by roughly 169 mg/dL.⁶

The differences went beyond the size of the spike. Patients who received Zilretta spent more time in their target glucose range (about 62 percent of the time versus 48 percent), were less likely to exceed 250 mg/dL (half the Zilretta group versus 93 percent of the standard group), and took longer to reach peak glucose levels: a median of 34 hours compared to 13 hours for the standard injection.⁶ For someone managing diabetes with insulin or oral medications, a more gradual and smaller glucose rise is much easier to handle than a sudden, dramatic spike. This finding is part of why some endocrinologists and rheumatologists specifically recommend the extended-release formulation for diabetic patients who need knee injections.

The study was small, with 18 patients in the Zilretta group and 15 in the standard group, so the exact numbers should be viewed as directional rather than definitive. But the pattern is consistent with what the pharmacokinetic data predict: less drug escaping from the joint into the bloodstream means less systemic cortisol-like activity, which means a smaller blood sugar impact.

Zilretta Is Only FDA-Approved for the Knee

One detail that sometimes gets lost is that Zilretta’s approval covers only the knee. It is not approved for hip osteoarthritis, shoulder OA, ankle OA, or any other joint. Any use outside the knee is considered off-label. Physicians are legally permitted to prescribe drugs off-label based on their clinical judgment, but insurance coverage for off-label uses can be difficult to obtain, and the evidence base is thinner.

Researchers have studied Zilretta’s extended-release formulation in the shoulder. A randomized trial comparing it with standard triamcinolone in patients with shoulder OA found that systemic exposure was about 1.5 times higher with the standard formulation, confirming that the extended-release microspheres reduce how much steroid leaks into the bloodstream even in a non-knee joint.⁷ But the pharmacokinetic advantage in a different joint does not automatically translate to approval. A recent review noted that “repeat-dose safety and indication expansion beyond the knee remain active needs best addressed through multicenter trials.”²

If your doctor suggests Zilretta for a non-knee joint, it is worth asking whether trial data support its use in that specific joint and whether your insurance will cover it. The pharmacokinetic rationale (keeping the steroid local and reducing systemic exposure) applies in theory to any joint, but each joint has different anatomy, fluid volume, and clearance dynamics. Knee data do not automatically transfer to hips or shoulders.

Joint Effusions and Zilretta

Some patients with knee OA deal with recurrent fluid buildup in the joint, known as effusion. Steroid injections are commonly used to reduce swelling, and there is emerging evidence that Zilretta may help with effusion specifically. A case report documented substantial reductions in aspirated fluid volume following Zilretta injections, with roughly 90 percent less fluid in both a patient’s left and right knees compared to pre-injection levels.⁸ This is preliminary data from a single patient, not a controlled trial, so it should not be treated as evidence that Zilretta reliably resolves effusions. But for patients whose primary complaint is swelling rather than pain, it is a data point worth discussing with a provider.

Timing Zilretta Before a Knee Replacement

If you are considering a total knee replacement (TKA) down the road, the timing of your last corticosteroid injection matters. A study of over 76,000 TKA patients found that receiving any corticosteroid injection within two weeks before surgery was an independent risk factor for postoperative infection, nearly tripling the odds.⁹ Injections given two to four weeks before surgery showed a trend toward increased risk as well, though it did not reach statistical significance. Beyond that four-week window, no elevated risk was detected.

This study looked at corticosteroid injections in general, not Zilretta specifically. But because Zilretta’s active ingredient remains in the joint for up to 12 weeks, the practical question is whether having a slowly dissolving steroid depot in the joint at the time of surgery poses different risks than a standard shot that clears quickly. There is no large study answering that question directly. Most orthopedic surgeons err on the side of caution and recommend waiting at least three months after any Zilretta injection before proceeding with knee replacement surgery. If you are getting Zilretta injections and surgery is on the horizon, bring up the timing explicitly with your surgeon.

Where Zilretta Fits Among Other Knee OA Injections

Zilretta is one option in a crowded field of injectable treatments for knee osteoarthritis. Standard corticosteroid injections remain the most widely used and least expensive. Hyaluronic acid (viscosupplementation) injections are another popular choice, though their efficacy has been debated for years. A review of the evidence suggested that hyaluronic acid injections might reduce pain in mild knee OA for up to 24 weeks, but cost-effectiveness is a significant concern.¹⁰ Platelet-rich plasma (PRP) injections are a newer alternative that shows promise in younger patients with mild OA, though more high-quality evidence is needed.

Each of these options has a different cost profile, a different mechanism, and a different typical retreatment schedule. Standard corticosteroid shots are often repeated every three to four months if needed, though many guidelines recommend limiting total injections per joint per year. Hyaluronic acid courses are typically given as a series of three to five weekly injections, repeated every six months to a year. PRP protocols vary widely. Zilretta sits in this landscape as a premium option: higher cost per injection, potentially fewer systemic side effects, and evidence supporting at least one repeat dose without cartilage harm. For patients whose primary concern is minimizing blood sugar disruption or systemic steroid exposure, it may be worth the added cost. For patients whose main goal is pain reduction, the advantage over a standard and much cheaper corticosteroid injection is less clear.

Insurance Coverage and Access

Zilretta’s cost is a frequent barrier. A single injection can run well over $500 at list price, compared to under $20 for a vial of standard triamcinolone acetonide. Insurance coverage varies considerably. Some insurers cover Zilretta as a preferred brand injection for knee OA. Others require prior authorization, step therapy (meaning you have to try a standard corticosteroid first and document that it was inadequate), or deny coverage altogether. Medicare Part B generally covers physician-administered injectable drugs for approved indications, so many Medicare beneficiaries can access Zilretta for knee OA, though copays still apply.

Because the FDA label describes a single injection without specifying repeat dosing, some insurers have used that wording to deny coverage for second or subsequent injections. If your insurer denies a repeat dose, your doctor’s office can appeal using the phase IIIb repeat-dosing study data as clinical justification. Success with appeals varies. If you are planning to get Zilretta and know you may want repeat injections, it is worth checking your insurer’s specific policy on repeat administration before your first shot, so you know what to expect financially going forward.